Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: We lack a comprehensive assessment of the risks and benefits of calorie restriction in older adults at high risk for cardiometabolic disease. Calorie restriction may reduce visceral adipose tissue (VAT) but also have negative effects on lean mass and quality of life.

Methods: We conducted a 52-week, randomized controlled trial involving 164 older adults with obesity taking at least one medication for hyperlipidemia, hypertension, or diabetes. Interventions included an exercise intervention alone (Exercise), or with diet modification and body weight maintenance (Maintenance), or with diet modification and energy restriction (Weight Loss). The primary outcome was change in VAT at 12 months. Secondary outcomes included cardiometabolic risk factors, functional status, and quality of life.

Results: A total of 148 participants had measured weight at 12 months. Despite loss of -1.6% ± 0.3% body fat and 4.1% ± 0.7% initial body weight, Weight Loss did not have statistically greater loss of VAT (-192.6 ± 185.2 cm3) or lean mass (-0.4 ± 0.3 kg) compared with Exercise (VAT = -21.9 ± 173.7 cm3; lean mass = 0.3 ± 0.3 kg). Quality of life improved in all groups with no differences between groups. No significant changes in physical function were observed. Weight Loss had significantly greater improvements in blood glucose (-8.3 ± 3.6 mg/dL, p < .05) and HDL-cholesterol (5.3 ± 1.9, p < .01) compared with Exercise. There were no group differences in the frequency of adverse events.

Conclusions: While moderate calorie restriction did not significantly decrease VAT in older adults at high risk for cardiometabolic disease, it did reduce total body fat and cardiometabolic risk factors without significantly more adverse events and lean mass loss.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861948PMC
http://dx.doi.org/10.1093/gerona/glw237DOI Listing

Publication Analysis

Top Keywords

calorie restriction
16
older adults
16
lean mass
16
weight loss
12
randomized controlled
8
controlled trial
8
adults high
8
high risk
8
risk cardiometabolic
8
cardiometabolic disease
8

Similar Publications

SGLT-2 inhibitors are a relatively new class of antidiabetic drugs. They activate a transcriptional response similar to calorie restriction characterized by the up-regulation of sensors involved in nutrient deprivation, such as SIRT1 and AMPK, and the down-regulation of mTOR, a molecule involved in nutritional excess signaling. The purpose of this review is to illustrate the main pathways of nutrient deprivation: a complex mechanistic framework partly responsible for the cardio-renal benefits that makes these drugs unique.

View Article and Find Full Text PDF

Background: Multiple non-pharmacological and nonsurgical interventions have demonstrated efficacy in improving abdominal obesity. However, the optimal intervention remains uncertain. This study aimed to assess the relative effectiveness and safety of these interventions in reducing waist circumference, waist-to-hip ratio, waist-to-height ratio (WHtR), body mass index (BMI), and body weight among adults with abdominal obesity.

View Article and Find Full Text PDF

Cancer cells are exposed to diverse metabolites in the tumour microenvironment that are used to support the synthesis of nucleotides, amino acids and lipids needed for rapid cell proliferation. In some tumours, ketone bodies such as β-hydroxybutyrate (β-OHB), which are elevated in circulation under fasting conditions or low glycemic diets, can serve as an alternative fuel that is metabolized in the mitochondria to provide acetyl-CoA for the tricarboxylic acid (TCA) cycle. Here we identify a non-canonical route for β-OHB metabolism that bypasses the TCA cycle to generate cytosolic acetyl-CoA.

View Article and Find Full Text PDF

Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.

Osteoporos Int

September 2025

Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.

Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO).

View Article and Find Full Text PDF

Low-protein Calorie-restriction Mitigates Diabetic Mice Kidney Injury via the Gut-Kidney Axis.

Int J Vitam Nutr Res

August 2025

Department of Endocrinology, Affiliated Hospital of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, 210028 Nanjing, Jiangsu, China.

Background: Dietary interventions have exhibited promise in restoring microbial balance in chronic kidney disease. A low-protein calorie-restricted diet can reduce kidney injury in diabetic rodents. However, whether the renoprotective effects of this dietary intervention in murine diabetic kidney disease models are linked to gut microbiota modulation remains to be determined.

View Article and Find Full Text PDF